Guidelines Updated for Diagnosis, Management of Focal Liver Lesions
By Elana Gotkine HealthDay Reporter
TUESDAY, July 23, 2024 -- In a clinical guideline issued by the American College of Gastroenterology and published online in the July issue of The American Journal of Gastroenterology, updated recommendations are presented for the diagnosis and management of the most common focal liver lesions (FLL).
Catherine Frenette, M.D., from the Family Health Centers of San Diego, and colleagues used the best evidence available to make diagnosis and management recommendations for the most common FLLs.
The authors recommended multiphasic contrast-enhanced imaging, preferably magnetic resonance imaging (MRI) or computed tomography performed with late arterial, portal venous, and delayed phases in patients with FLL of uncertain etiology. In patients with hepatic adenomas, discontinuation of oral contraceptives or intrauterine devices that are hormone-impregnated is recommended. Weight loss is suggested for overweight or obese patients with hepatic adenomas. To accurately distinguish hepatic adenomas from other benign or malignant liver lesions, multiphasic liver imaging (preferably MRI) is suggested over standard cross-sectional imaging modalities. Discontinuation of exogenous hormones is suggested and weight loss advised, if applicable, in women with hepatic adenomas <5 cm. Continued imaging surveillance is recommended every three to six months for at least one year in patients with cirrhosis or chronic hepatitis B who meet criteria for hepatocellular carcinoma surveillance and have a suspected hemangioma.
"Despite the radiographic results, patients will continue to rely on their providers to make the best recommendations for ongoing care, which in the ideal scenario is the reassurance that no further follow-up is required, especially in patients without underlying comorbidities," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
FRIDAY, July 26, 2024 -- In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with...
Racial Disparities Identified for Time to Diagnosis of Huntington Disease
FRIDAY, July 26, 2024 -- Black individuals are diagnosed with Huntington disease (HD) at least one year later than White individuals, according to a study published online June 21...
Widespread Brain Structural Alterations Seen in Conduct Disorders
FRIDAY, July 26, 2024 -- There are widespread brain structural alterations apparent in conduct disorders, mostly in surface area, according to a study published in the August...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.